Injection of SHR-A1811 Versus Physician Choiced Treatment in Patients With Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-fu,
A phase 3 trial of Trastuzumab rezetecan, Trifluridine/tipiracil, Regorafenib in colorectal cancer, run by Suzhou Suncadia Biopharmaceuticals Co., Ltd., active and no longer recruiting.
Overview
Injection of SHR-A1811 Versus Physician Choiced Treatment in Patients With Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-fu, and Irinotecan is a phase 3 interventional study registered as NCT06199973 by Suzhou Suncadia Biopharmaceuticals Co., Ltd., with 130 participants enrolled, started 2024-03-01 and due to reach its primary completion in 2026-04. Interventions recorded: SHR-A1811, TAS-102, Regorafenib , Fruquintinib. Conditions listed: Advanced Colorectal Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients With Refractory Advanced/Metastatic Colorectal Cancer
Shares Trifluridine/tipiracil, Fruquintinib, Colorectal cancer.
- TrialTATE and Pembrolizumab (MK3475) in mCRC and NSCLC
Shares Trifluridine/tipiracil, Regorafenib, Colorectal cancer.
- TrialA Study of SHR-4610 Injection in Patients With Advanced Solid Tumors
Shares Trastuzumab rezetecan, Jiangsu Hengrui Pharmaceuticals.
- TrialA Clinical Study of SHR-A1811 in Combination With Chemotherapy and Bevacizumab Versus Standard Therapy as First-Line Treatment for Advanced Colorectal
Shares Trastuzumab rezetecan, Jiangsu Hengrui Pharmaceuticals, Colorectal cancer.
- TrialA Phase II Trial of SHR-A1811 in HER2-Expressing Recurrent/Metastatic Cervical Cancer
Shares Trastuzumab rezetecan, Jiangsu Hengrui Pharmaceuticals.
- TrialPhase II Clinical Study of SHR-A1811 in Patients With HER2 Expression / Amplification of Locally Advanced Unresectable or Recurrent Metastatic Biliary Tract Cancer
Shares Trastuzumab rezetecan, Jiangsu Hengrui Pharmaceuticals.
- TrialA Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer.
Shares Fruquintinib, Colorectal cancer.
- TrialADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors
Shares Trifluridine/tipiracil, Fruquintinib.